Anti-Müllerian Hormone Predicts Menopause: A Long-Term Follow-Up Study in Normoovulatory Women

Broer, Simone L.; Eijkemans, Marinus J.C.; Scheffer, G.J.; Rooij, Iris A. L. M. van; Vet, Annemarie de; Themmen, Axel P. N.; Laven, Joop S.E.; Jong, Frank H. de; Velde, Egbert R. te; Fauser, Bart C.J.M.; Broekmans, Frank J.

doi:10.1210/jc.2010-2776

Cited by 308 publications

(211 citation statements)

References 39 publications

Supporting

Mentioning

196

Contrasting

Unclassified

Order By: Relevance

“…In women, the highest value of AMH is attained after puberty and subsequently decrease with age, likely reflecting the agerelated decline in ovarian reserve [1]. Serum AMH levels estimate ovarian reserve and the proximity of menopause [3]. Although we and others [4][5][6][7][8][9][10][11][12] have recently shown that Capsule AMH of 0.2 ng/mL appears to be a clinically meaningful cutoff for predicting a relatively "good" clinical pregnancy rate in women with severely diminished ovarian reserve at our practice.…”

Section: Introductionmentioning

confidence: 82%

Determining an anti-mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve

Merhi

Zapantis

Berger

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Serum anti-Mullerian hormone (AMH) levels estimate ovarian reserve. The purpose of this study was to identify a minimum serum AMH level that correlates with acceptable clinical pregnancy rate (CPR) in women with severe diminished ovarian reserve (DOR) undergoing in vitro fertilization (IVF). Methods(s) A historical cohort of severe DOR participants (age ≥35) with day 3 FSH of >10 ng/mL were included (n =120). Participants were categorized into 3 groups: AMH <0.2 (Group 1, n =38), AMH=0.2-0.79 (Group 2, n =57) and AMH≥0.8 (Group 3, n =25) ng/mL. The main outcome was CPR. The number of retrieved and mature oocytes, transferred embryos, spontaneous abortion (SAB) and live birth (LB) rates were also evaluated. Result(s) Among the three groups, there was no difference in day 3 FSH and estradiol, total gonadotropins dose used per cycle, or LB. Participants in Group 1 were two years older than those in Group 2 and had significantly higher BMI than those in Groups 2 and 3. The three groups significantly differed in AFC (Group 1< Group 2< Group 3; p =0.001) and cycle cancellation rate (Group 1> Group 2> Group 3; p =0.006), and had a trend toward significance in SAB rate (Group 1> Group 2> Group 3; p =0.06). Group 3 had significantly more retrieved and mature oocytes than Groups 1 or 2. Group 2 and 3 had significantly higher CPR per cycle start compared to Group 1. Although Group 2 had significantly fewer oocytes retrieved and mature oocytes than Group 3, CPR per cycle start for both groups was not different. ROC curve indicated that the point of maximal inflection between lower and higher CPR represents an AMH value of 0.2 ng/mL. Conclusion(s) AMH of 0.2 ng/mL appears to be a meaningful threshold for predicting CPR in women with severe DOR at our practice. This information can be crucial during the precycle counseling of these women.

show abstract

Section: Introductionmentioning

confidence: 82%

Determining an anti-mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve

Merhi

Zapantis

Berger

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…This has led to speculation that serum AMH levels could improve prediction of the onset of menopause. In long-term follow-up studies of 9 and 11 years, women in certain age groups who had lower AMH levels may have had an earlier onset of menopause [46,47], and recent multivariate prediction models including serum AMH were shown to more accurately forecast early or late menopause [48,49].…”

Section: Prediction Of Menopause/primary Ovarian Insufficiency (Poi)mentioning

confidence: 99%

Anti‐Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Iwase

Nakamura

Osuka

et al. 2015

Reprod Medicine & Biology

View full text Add to dashboard Cite

Ovarian reserve reflects the quality and quantity of available oocytes. This reserve has become indispensable for the better understanding of reproductive potential. Measurement of the serum anti-Müllerian hormone (AMH) level allows quantitative evaluation of ovarian reserve. It has been applied to a wide range of clinical conditions, and it is well established that the measurement of serum AMH levels is more useful than qualitative evaluation based on the menstrual cycle. AMH levels are monitored during infertility treatments; in patients undergoing medically assisted reproductive technology; and in the diagnosis of ovarian failure, polycystic ovarian syndrome, and granulosa cell tumor. It is also useful in the evaluation of iatrogenic ovarian damage. Population-based studies have indicated a potential role for serum AMH in the planning of reproductive health management. While AMH is currently the best measure of ovarian reserve, its predictive value for future live births remains controversial. Furthermore, there is a serious practical issue in the interpretation of test results, as currently available assay kits use different assay ranges and coefficients of variation due to the absence of an international reference standard. The pros and cons of the serum AMH level as a definitive measure of ovarian reserve merits further review in order to guide future research.

show abstract

“…However, as early as 36 weeks gestation, female fetuses begin producing AMH, which steadily increases in production until follicles reach the antral phase [6]. Following an incremental increase in AMH levels throughout a women's reproductive time span, there is a steady decline in levels until it becomes undetectable, which correlates with the onset of menopause [7]. This rise and fall of the AMH level corresponds with the number of oocytes remaining in the ovary [8].…”

Section: Introductionmentioning

confidence: 99%

Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide

Tobler

Shoham

Christianson

et al. 2015

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The aim of this study is to assess how anti-mullerian hormone (AMH) is used worldwide to test ovarian reserve and guide in vitro fertilization (IVF) cycle management. Methods An internet-based survey was sent electronically to registered IVF providers within the IVF-Worldwide.com network. This survey consisted of nine questions which assessed the clinics' use of AMH. The questionnaire was completed online through the IVF-Worldwide.com website, and quality assurance tools were used to verify that only one survey was completed per clinical IVF center. Results are reported as the proportion of IVF cycles represented by a particular answer choice. Results Survey responses were completed from 796 globally distributed IVF clinics, representing 593,200 IVF cycles worldwide. Sixty percent of the respondent-IVF cycles reported to use AMH as a first line test, and 54 % reported it as the best test for evaluating ovarian reserve. Eighty-nine percent reported that AMH results were extremely relevant or relevant to clinical practice. However in contrast, for predicting live birth rate, 81 % reported age as the best predictor. Conclusions AMH is currently considered a first line test for evaluating ovarian reserve and is considered relevant to clinical practice by the majority of IVF providers.

show abstract

Anti-Müllerian Hormone Predicts Menopause: A Long-Term Follow-Up Study in Normoovulatory Women

Abstract: AMH is highly predictive for timing of menopause. Using age and AMH, the age range in which menopause will subsequently occur can be individually calculated.

Cited by 308 publications

References 39 publications

Determining an anti-mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve

Determining an anti-mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve

Anti‐Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide

Contact Info

Product

Resources

About